Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy

Annals of Oncology

Volumn 21, Issue 10, 2010, Pages 1982-1989

  Mitchell, C L ^a   O'connor, J P B ^a   Jackson, A ^a   Parker, G J M ^a   Roberts, C ^a   Watson, Y ^a   Cheung, S ^a   Davies, K ^a   Buonaccorsi, G A ^a   Clamp, A R ^a   Hasan, J ^a   Byrd, L ^a   Backen, A ^b   Dive, C ^b   Jayson, G C ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Angiogenesis; Biomarkers; DCE MRI; Ovarian

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; TUMOR MARKER; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADVANCED CANCER; ANGIOGENESIS; ARTICLE; BLOOD VOLUME; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL MEMBRANE PERMEABILITY; CONTRAST ENHANCEMENT; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT CANCER; SEROLOGY; TUMOR VOLUME;

EID: 77955428008     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq079     Document Type: Article

References (25)

1. National Statistic Office. Office for National Statistics 2008 Mortality Statistics: Cause, England and Wales. Series DH2, in edition 2008. London: National Statistics 2006.
2. Blackledge G, Lawton F, Redman C, Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 1989; 59: 650-653.
3. Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389-393.
4. Gore ME, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990; 36: 207-211.
5. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]. Ann Oncol 1997; 8: 963-968.
6. Cannistra SA, Matulonis UA, Penson RT et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25: 5180-5186.
7. Drevs J, Siegert P, Medinger M et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007; 25: 3045-3054.
8. Jayson GC, Zweit J, Jackson A et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 2002; 94: 1484-1493.
9. Ton NC, Parker GJ, Jackson A et al. Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2. Clin Cancer Res 2007; 13: 7113-7118.
10. Mullamitha SA, Ton NC, Parker GJ et al. Phase I evaluation of a fully human antialphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res 2007; 13: 2128-2135.
11. Fram EK, Herfkens RJ, Johnson GA et al. Rapid calculation of T1 using variable flip angle gradient refocused imaging. Magn Reson Imaging 1987; 5: 201-208.
12. Jayson GC, Parker GJ, Mullamitha S et al. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 2005; 23: 973-981.
13. O'Connor JP, Jayson GC, Jackson A et al. Enhancing fraction predicts clinical outcome following first-line chemotherapy in patients with epithelial ovarian carcinoma. Clin Cancer Res 2007; 13: 6130-6135.
14. Tofts PS, Brix G, Buckley DL et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10: 223-232.
15. Parker GJM, Buckley DL. Tracer Kinetic Modelling for T1-weighted DCE-MRI. In Jackson A, Parker GJM, Buckley DL (eds), Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Oncology. Heidelberg: Springer 2005.
16. Paul ST. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997; 7: 91-101.
17. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997; 7: 91-101.
18. Parker GJ, Jackson A, Waterton JC, Buckley DL. Automated arterial input function extraction for T1-weighted DCE-MRI. Proceedings of the International Society for Magnetic Resonance in Medicine (Abstr 1264). Toronto 2003.
19. Parker GJ, Roberts C, Macdonald A et al. Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. Magn Reson Med 2006; 56: 993-1000.
20. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
21. WHO. The WHO Handbook for Reporting Results of Cancer Treatment. Geneva: Offset Publications 1979.
22. Backen AC, Cummings J, Mitchell C et al. Fit-for-purpose' validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use. J Immunol Methods 2009; 342: 106-114.
23. North S, Moenner M, Bikfalvi A. Recent developments in the regulation of the angiogenic angiogenic switch by cellular stress factors in tumors. Cancer Lett 2005; 218:1-14.
24. Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83-95.
25. Rustin G. J vdBME. A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials). J Clin Oncol 2009; 27: 18s (suppl; Abstr 1).